maltase

(redirected from Alpha-glucosidase)
Also found in: Dictionary, Medical, Wikipedia.

maltase

[′mȯl‚tās]
(biochemistry)
An enzyme that catalyzes the conversion of maltose to dextrose.
References in periodicals archive ?
Pompe disease (glycogen storage disease Type II, acid maltase deficiency, and OMIM #232300) is a rare, progressive, autosomal recessive metabolic disorder caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA).
Pompe disease is caused by mutations in the gene encoding the lysosomal enzyme alpha-glucosidase, or GAA, which results in a deficiency of GAA protein and leads to the accumulation of glycogen.
Pompe disease is caused by mutations in the gene that encodes the enzyme acid alpha-glucosidase, or GAA, which is responsible for degrading lysosomal glycogen.
In our study, we generally showed statistically significant correlations between increased resistance to 5-fluorocytosine, ketoconazole, miconazole, fluconazole, itraconazole and higher activity of alpha-galactosidase, alpha-glucosidase, leucine arylamidase, beta-glucuronidase, beta-glucosidase, chymotrypsin, esterase, acid phosphatase, alkaline phosphatase, naphthyl phosphohydrolase, N-acetyl-beta-D-glucosidase, and trypsin for isolates from hand surfaces.
Antisense Oligonucleotide to Activate Lysosomal Alpha-Glucosidase for Pompe Disease - Drug Profile 42
Alpha-glucosidase inhibitory activity of bromophenol purified from the red alga Polyopes lancifolia.
Pompe disease is a progressive, debilitating and often fatal neuromuscular disease caused by a genetic deficiency or dysfunction of the lysosomal enzyme acid alpha-glucosidase (GAA) affecting an estimated 50,000 people worldwide.
Keywords: Alpha-glucosidase inhibitors, DPP4 inhibitors, GLP1 receptor agonists, Metformin, Pioglitazone, Pramlintide, SGLT2 inhibitors.
Both dipeptidyl peptidase-4 (DPP-4) inhibitors and alpha-glucosidase inhibitors (AGIs) appear to be weight-neutral or to induce minimal changes in weight.
Molecular basis for the recognition of long-chain substrates by plant & alpha-glucosidase.
The global diabetes drugs and devices market report estimates the market size (Revenue USD million - 2013 to 2020) for key market segments based on the drug type (insulin derivatives - short-acting, intermediate-acting, long-acting, premixed, and rapid-acting insulin; oral anti-diabetes drugs - alpha-glucosidase inhibitors, biguanides, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylureas, thiazolidinediones; and non-insulin injectable anti-diabetes drugs - GLP-1 analogs), device type (diabetes monitoring and diagnostic devices - analog glucose meter, continuous glucose monitoring devices, glucose test strips, lancets and lancing devices; insulin delivery devices - insulin injectors, pens, pumps, syringes, etc.
In vitro alpha-glucosidase inhibitory activity of phenolic constituents from aerial parts of Polygonum hyrcanicum.